GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Polaris Group (TPE:6550) » Definitions » Common Stock

Polaris Group (TPE:6550) Common Stock : NT$7,461.95 Mil (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Polaris Group Common Stock?

Polaris Group's quarterly common stock increased from Mar. 2024 (NT$7,444.21 Mil) to Jun. 2024 (NT$7,458.33 Mil) and increased from Jun. 2024 (NT$7,458.33 Mil) to Sep. 2024 (NT$7,461.95 Mil).

Polaris Group's annual common stock increased from Dec. 2021 (NT$7,188.45 Mil) to Dec. 2022 (NT$7,420.48 Mil) and increased from Dec. 2022 (NT$7,420.48 Mil) to Dec. 2023 (NT$7,437.59 Mil).


Polaris Group Common Stock Historical Data

The historical data trend for Polaris Group's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polaris Group Common Stock Chart

Polaris Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,529.01 6,529.01 7,188.45 7,420.48 7,437.59

Polaris Group Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,436.36 7,437.59 7,444.21 7,458.33 7,461.95

Polaris Group Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Polaris Group Business Description

Traded in Other Exchanges
N/A
Address
NO.298, Ruiguang Road, 7th floor, Neihu District, Taipei, TWN
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.

Polaris Group Headlines

No Headlines